Illumina (ILMN) said Monday it is starting a $100 million cost reduction program and lowering its fiscal 2025 non-GAAP earnings forecast.
The cost savings are expected to reduce the impact of a potential reduction in revenue and related operating income from the company's Greater China business after the country placed a ban on imports of its genetic sequencing instruments.
The company now expects fiscal 2025 adjusted EPS of about $4.50, compared with $4.50 to $4.65 expected previously. Analysts polled by FactSet expect $4.51.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.